Stem Cell Authority (Stem Cell Authority) Debt-to-Revenue : 0.00 (As of . 20)

View and export this data going back to . Start your Free Trial

What is Stem Cell Authority Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Stem Cell Authority's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was $0.00 Mil. Stem Cell Authority's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was $0.00 Mil. Stem Cell Authority's annualized Revenue for the quarter that ended in . 20 was $0.00 Mil.

Stem Cell Authority Debt-to-Revenue Historical Data

The historical data trend for Stem Cell Authority's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stem Cell Authority Debt-to-Revenue Chart

Stem Cell Authority Annual Data

Trend

Debt-to-Revenue

Stem Cell Authority Quarterly Data

Debt-to-Revenue

Competitive Comparison of Stem Cell Authority's Debt-to-Revenue

For the Medical Care Facilities subindustry, Stem Cell Authority's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Stem Cell Authority's Debt-to-Revenue Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Stem Cell Authority's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Stem Cell Authority's Debt-to-Revenue falls into.

Stem Cell Authority Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Stem Cell Authority's Debt-to-Revenue for the fiscal year that ended in . 20 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(	+	)	/	N/A
	=	N/A

Stem Cell Authority's annualized Debt-to-Revenue for the quarter that ended in . 20 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(	+	)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (. 20) Revenue data.

Stem Cell Authority Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Stem Cell Authority's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Stem Cell Authority (Stem Cell Authority) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Stem Cell Authority Ltd (OTCPK:SCAL) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Room 1907, No. 1038, Westgate Mall, Jing'An District, Shanghai, CHN, 200041

Website

https://www.stemcellauthority.com

Stem Cell Authority Ltd operates in the medical care industry. The Company is a clinical stage biopharmaceutical company committed to the research and development of immune system disease treatments using small molecules and stem cell technology. The company is engaged in finding stem cell doctors and offers stem cell therapy for hips, knees, and elbows. The firm also offers stem cell treatment for chronic pain and arthritis.

Stem Cell Authority (Stem Cell Authority) Headlines

No Headlines